Contact

In the news

22.10.2024
Visgenx To Present At Eyecelerator At The American Academy Of Ophthalmology Annual...
»
09.05.2024
Visgenx Announces Presentation of Data Supporting Potential of its Synthetic AAV DNA...
»
09.05.2024
ASGCT 2024 Poster Abstract
»
07.05.2024
ELOVL2 Enzyme Product Improves Retinal Function and Rejuvenates Retina Architecture in an...
»
04.05.2024
Visgenx to Present at the Second Annual 2024 Cell & Gene Therapy...
»
08.04.2024
Visgenx selected as a ‘2024 Cool Company’
»
07.12.2023
Visgenx and Charles River Announce Expansion of Gene Therapy Manufacturing Alliance
»
15.11.2023
Visgenx to Present at the 4th Annual Dry AMD Therapeutic Development Summit
»
25.10.2023
Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2...
»
11.09.2023
Visgenx Poster: Advancing Next Generation Therapies, West Coast Symposium
»
11.09.2023
Visgenx Presents Poster at the Cell and Gene Therapy: Advancing Next Generation...
»
29.06.2023
Visgenx Announces Positive Results from a Key Translational Study for its Gene...
»
05.06.2023
Visgenx Appoints William Pedranti as Chief Executive Officer
»
24.05.2023
Attending BIO 2023? Click below to send Visgenx a meeting request in the...
»
15.05.2023
Visgenx to present at the American Society of Gene and Cell Therapy...
»
Load More

Reversal in Focus.

We aim to “turn back the clock” to a more youthful level of ELOVL2 expression.

Contact us »